COSCIENS Biopharma sets June 17, 2026 virtual AGM

COSCIENS Biopharma Inc. has scheduled its annual general and special meeting of shareholders as a virtual meeting on June 17, 2026.

Rhea-AI Filing Summary

COSCIENS Biopharma Inc. has scheduled its annual general and special meeting of shareholders as a virtual meeting on June 17, 2026. The company set May 18, 2026 as the record date for notice, voting, and beneficial ownership determination, meaning only holders of common shares on that date are entitled to receive materials and vote. The filing also notes that proxy-related materials will not be sent directly to non-objecting beneficial owners, and the issuer will pay for delivery to objecting beneficial owners.

Key Figures

Meeting date: June 17, 2026 Record date for notice and voting: May 18, 2026 Beneficial ownership determination date: May 18, 2026

3 metrics

Meeting date June 17, 2026 Annual general and special meeting of shareholders

Record date for notice and voting May 18, 2026 Determines eligible shareholders for meeting

Beneficial ownership determination date May 18, 2026 Used for determining beneficial owners entitled to vote

Key Terms

Annual General and Special Meeting, Beneficial Ownership Determination Date, Notice and Access (NAA), NOBO, +1 more

5 terms

Annual General and Special Meeting regulatory

"Meeting Type | | Annual General and Special Meeting"

A combined annual general and special meeting is a formal gathering of a company’s shareholders to handle routine yearly business—like approving financial statements and electing directors—and to decide on one-off or significant matters that need shareholder approval, such as major asset sales or changes to corporate rules. Investors care because votes cast there can change who runs the company, alter its strategy or capital structure, and signal broader shareholder support or opposition, much like homeowners voting on routine upkeep and a special renovation in a neighborhood association.

Beneficial Ownership Determination Date regulatory

"Beneficial Ownership Determination Date | | May 18, 2026"

Notice and Access (NAA) regulatory

"Notice and Access (NAA) Requirements:"

NOBO regulatory

"Issuer sending proxy related materials directly to NOBO:"

OBO regulatory

"Issuer paying for delivery to OBO:"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is COSCIENS Biopharma Inc. (CSCI) holding its 2026 shareholder meeting?

COSCIENS Biopharma Inc. will hold its annual general and special meeting on June 17, 2026 as a virtual meeting. This meeting covers regular annual business and special matters requiring shareholder approval, with participation limited to shareholders of record as of the specified record date.

What is the record date for COSCIENS Biopharma (CSCI) 2026 shareholder meeting?

The record date for notice and voting at COSCIENS Biopharma’s 2026 meeting is May 18, 2026. Only shareholders who hold common shares on that date are entitled to receive the notice of meeting and vote on the items presented at the virtual meeting.

How will COSCIENS Biopharma (CSCI) 2026 shareholder meeting be held?

The 2026 annual general and special meeting of COSCIENS Biopharma will be held as a virtual meeting. Shareholders of record on May 18, 2026 can participate online, in line with details provided in the Notice of Meeting distributed through the company’s transfer agent, Computershare.

Does COSCIENS Biopharma (CSCI) use notice-and-access for 2026 meeting materials?

For the 2026 shareholder meeting, COSCIENS Biopharma is not using notice-and-access for either beneficial or registered holders. This means proxy-related materials are expected to be sent in full rather than primarily made available online under notice-and-access rules.

How are proxy materials delivered to COSCIENS Biopharma (CSCI) beneficial owners?

COSCIENS Biopharma will not send proxy materials directly to non-objecting beneficial owners (NOBOs). However, the issuer will pay for delivery of materials to objecting beneficial owners (OBOs), as arranged through its transfer agent, Computershare, for the June 17, 2026 meeting.

What securities are eligible to vote at COSCIENS Biopharma (CSCI) 2026 meeting?

The voting security is the company’s common shares, identified with CUSIP 22112H101 and ISIN CA22112H1010. Holders of these common shares as of May 18, 2026 are entitled to receive meeting materials and vote at the virtual annual general and special meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:45 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2026

Commission File Number: 001-38064

COSCIENS Biopharma Inc.

(Translation of registrant’s name into English)

c/o Borden Ladner Gervais, LLP

22 Adelaide St. West, Suite 3400

Bay Adelaide Centre, East Tower

Toronto ON M5H 4E3

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On May 8, 2026, COSCIENS Biopharma Inc. (the “Company”) issued a Notice of Annual General and Special Meeting of Shareholders (the “Notice of Meeting”) in connection with the annual general and special meeting of shareholders of the Company (the “Meeting”). A copy of the Notice of Meeting is attached hereto as Exhibit 99.1, which is incorporated by reference herein.

DOCUMENTS INDEX

Exhibit		Description
99.1		Notice of Annual General and Special Meeting of Shareholders

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COSCIENS Biopharma Inc.
Date: May 8, 2026	By:	/s/ Giuliano La Fratta
	Name:	Giuliano La Fratta
	Title:	Chief Financial Officer

Exhibit 99.1

May 8, 2026
650 De Maisonneuve Blvd., 7th Floor
Montreal QC, H3A 3T2
www.computershare.com

To: All Canadian Securities Regulatory Authorities

Subject: COSCIENS Biopharma Inc.

Dear Sir/Madam:

We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:

Meeting Type :		Annual General and Special Meeting
Record Date for Notice of Meeting :		May 18, 2026
Record Date for Voting (if applicable) :		May 18, 2026
Beneficial Ownership Determination Date :		May 18, 2026
Meeting Date :		June 17, 2026
Meeting Location (if available) :		Virtual Meeting
Issuer sending proxy related materials directly to NOBO:		No
Issuer paying for delivery to OBO:		Yes

Notice and Access (NAA) Requirements:
NAA for Beneficial Holders		No
NAA for Registered Holders		No

Voting Security Details:

Description		CUSIP Number		ISIN
COMMON SHARES		22112H101		CA22112H1010

Sincerely,

Computershare

Agent for COSCIENS Biopharma Inc.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 11.5 KB
• EX-99 GRAPHIC 5.0 KB